HOOKIPA PHARMA INC (HOOK) Stock Fundamental Analysis
NASDAQ:HOOK - Nasdaq - US43906K2096 - Common Stock - Currency: USD
We assign a fundamental rating of 4 out of 10 to HOOK. HOOK was compared to 572 industry peers in the Biotechnology industry. While HOOK has a great health rating, there are worries on its profitability. HOOK is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year HOOK has reported negative net income.
HOOK had a negative operating cash flow in the past year.
HOOK had negative earnings in each of the past 5 years.
HOOK had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
HOOK has a Return On Assets (-39.53%) which is in line with its industry peers.
HOOK has a Return On Equity of -60.40%. This is in the better half of the industry: HOOK outperforms 60.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.53% | ||
| ROE | -60.4% | ||
| ROIC | N/A |
ROA(3y)-49.57%
ROA(5y)-40.42%
ROE(3y)-79.53%
ROE(5y)-60.66%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HOOK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
HOOK does not have a ROIC to compare to the WACC, probably because it is not profitable.
HOOK has less shares outstanding than it did 1 year ago.
HOOK has less shares outstanding than it did 5 years ago.
HOOK has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -4.80, we must say that HOOK is in the distress zone and has some risk of bankruptcy.
HOOK has a worse Altman-Z score (-4.80) than 60.88% of its industry peers.
HOOK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.8 |
ROIC/WACCN/A
WACC10.33%
2.3 Liquidity
A Current Ratio of 3.26 indicates that HOOK has no problem at all paying its short term obligations.
HOOK's Current ratio of 3.26 is on the low side compared to the rest of the industry. HOOK is outperformed by 61.42% of its industry peers.
HOOK has a Quick Ratio of 3.26. This indicates that HOOK is financially healthy and has no problem in meeting its short term obligations.
HOOK has a Quick ratio (3.26) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.26 | ||
| Quick Ratio | 3.26 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 55.18% over the past year.
Looking at the last year, HOOK shows a very strong growth in Revenue. The Revenue has grown by 143.19%.
Measured over the past years, HOOK shows a very strong growth in Revenue. The Revenue has been growing by 21.41% on average per year.
EPS 1Y (TTM)55.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.29%
Revenue 1Y (TTM)143.19%
Revenue growth 3Y0.93%
Revenue growth 5Y21.41%
Sales Q2Q%-31.51%
3.2 Future
The Earnings Per Share is expected to grow by 12.98% on average over the next years. This is quite good.
Based on estimates for the next years, HOOK will show a small growth in Revenue. The Revenue will grow by 1.23% on average per year.
EPS Next Y81.65%
EPS Next 2Y32.3%
EPS Next 3Y22.38%
EPS Next 5Y12.98%
Revenue Next Year160.99%
Revenue Next 2Y1.16%
Revenue Next 3Y-62.4%
Revenue Next 5Y1.23%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
HOOK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year HOOK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
HOOK's earnings are expected to grow with 22.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.3%
EPS Next 3Y22.38%
5. Dividend
5.1 Amount
HOOK does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HOOKIPA PHARMA INC
NASDAQ:HOOK (2/5/2025, 10:43:08 AM)
1.91
+0.03 (+1.6%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners36.89%
Inst Owner Change-0.02%
Ins Owners1.93%
Ins Owner Change0%
Market Cap23.02M
Analysts81.82
Price Target25.25 (1221.99%)
Short Float %1.92%
Short Ratio1.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.68%
Min EPS beat(2)-18.98%
Max EPS beat(2)15.62%
EPS beat(4)2
Avg EPS beat(4)47.52%
Min EPS beat(4)-18.98%
Max EPS beat(4)205.21%
EPS beat(8)4
Avg EPS beat(8)26.6%
EPS beat(12)6
Avg EPS beat(12)15.8%
EPS beat(16)9
Avg EPS beat(16)12.77%
Revenue beat(2)0
Avg Revenue beat(2)-54.2%
Min Revenue beat(2)-82.17%
Max Revenue beat(2)-26.23%
Revenue beat(4)2
Avg Revenue beat(4)283.13%
Min Revenue beat(4)-82.17%
Max Revenue beat(4)1181.48%
Revenue beat(8)4
Avg Revenue beat(8)140.52%
Revenue beat(12)5
Avg Revenue beat(12)82.12%
Revenue beat(16)8
Avg Revenue beat(16)62.77%
PT rev (1m)-22.17%
PT rev (3m)-44.75%
EPS NQ rev (1m)38.36%
EPS NQ rev (3m)-315.76%
EPS NY rev (1m)-1.82%
EPS NY rev (3m)29.91%
Revenue NQ rev (1m)4.06%
Revenue NQ rev (3m)22.49%
Revenue NY rev (1m)0.52%
Revenue NY rev (3m)-2.57%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.46 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.32 | ||
| P/tB | 0.32 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.72
EYN/A
EPS(NY)-2.2
Fwd EYN/A
FCF(TTM)-5.63
FCFYN/A
OCF(TTM)-5.58
OCFYN/A
SpS4.15
BVpS5.96
TBVpS5.96
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.53% | ||
| ROE | -60.4% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-49.57%
ROA(5y)-40.42%
ROE(3y)-79.53%
ROE(5y)-60.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 18.32% | ||
| Cap/Sales | 1.22% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.26 | ||
| Quick Ratio | 3.26 | ||
| Altman-Z | -4.8 |
F-Score4
WACC10.33%
ROIC/WACCN/A
Cap/Depr(3y)175.89%
Cap/Depr(5y)144.73%
Cap/Sales(3y)41.36%
Cap/Sales(5y)30.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.29%
EPS Next Y81.65%
EPS Next 2Y32.3%
EPS Next 3Y22.38%
EPS Next 5Y12.98%
Revenue 1Y (TTM)143.19%
Revenue growth 3Y0.93%
Revenue growth 5Y21.41%
Sales Q2Q%-31.51%
Revenue Next Year160.99%
Revenue Next 2Y1.16%
Revenue Next 3Y-62.4%
Revenue Next 5Y1.23%
EBIT growth 1Y43.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.99%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-21.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-45.03%
OCF growth 3YN/A
OCF growth 5YN/A